Status:
UNKNOWN
Anal Injury Screening for High Risk HPV
Lead Sponsor:
Hospital General de México Dr. Eduardo Liceaga
Conditions:
Anal Injury
Anal Cancer
Eligibility:
All Genders
30-65 years
Phase:
NA
Brief Summary
The diagnosis of anal cancer is superior with the Anal Test system compared to liquid cytology and anoscopy.
Detailed Description
DESIGN METHODOLOGY: Prospective, cross-sectional, comparative, double-blind, randomized. STUDY POPULATION: Group 1, 250 HIV negative patients (150 men and 100 women) from the oncology service who ag...
Eligibility Criteria
Inclusion
- Men and women between 30 and 65 years old.
- They agree to participate in the study and sign informed consent.
- They have not received previous treatments for HPV or had previous intraepithelial lesions or anal cancer.
- Immunosuppressed patients.
- Women with LIAG of the genital tract (cervix, vagina, or vulva).
- Patients who have had anal intercourse
Exclusion
- Patients sexually inactive
- Subjects who had anal sex in less than 24 hours prior to the study.
- Patients with local medication application (enemas, suppositories).
Key Trial Info
Start Date :
August 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2021
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04512508
Start Date
August 30 2020
End Date
January 31 2021
Last Update
August 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General de México Eduardo Liceaga
Mexico City, Mexico, 06720